Group items tagged

Adenovirus Infection in Pediatric Populations is organized by Nursing CE Central, this course is intended for Nurses.

MI CARES: Prevention and Public Health is organized by Michigan State University College of Osteopathic Medicine (MSUCOM)

COPD - Chronic Obstructive Pulmonary Disease is organized by AchieveCE, this Course has been approved with a maximum of 4.0 Contact Hours

Emergency Medicine and Infectious Diseases: Current Issues and Common Challenges is organized by American Medical Seminars, Inc. from Jun 19 - 22, 2023 in Sarasota, Florida, USA

The Department of Health and Social Care (DHSC) has invited views of healthcare professionals and others to tackle the six major health conditions which drive-ill health and contribute to the burden of disease in England. The six major health conditions - cancer; cardiovascular diseases including stroke and diabetes; chronic respiratory diseases; dementia; mental ill-health and musculoskeletal disorders - affect millions of people in England with data showing that one in four suffer from two or more of these major long-term conditions. Recognising the pressure these conditions are putting on the NHS, the government is seeking views on a new strategy to tackle them that will focus not only on treatment but also on prevention. Government is particularly interested in hearing from those who suffer from, care for or provide treatment to people who suffer from multiple long-term conditions. This is to ensure the Major Conditions Strategy is one that will better prevent, diagnose, manage and treat these conditions. Contributions are also encouraged from those working in NHS bodies, local government, the voluntary and community sector, and wider industry, on how best to tackle suffering from one or more of these major conditions. Particularly, it is seeking perspectives on how government and the NHS can work better together with different organisations and sectors to improve the nation's health.

While research on particular supplements is optimistic, it's still too early to declare if they benefit. For centuries, turmeric herb has been used in Ayurveda, traditional Chinese, and Unani medicine to alleviate arthritis pain and other ailments. Modern-day science indicates that its active compound, curcumin, may help resist inflammation. Even though there's little research on turmeric for fibromyalgia and chronic fatigue syndrome, it may be worth trying since curcumin works like a pain-killing agent in your body. To keep things relatively simple, I'll stick to research while telling you the 'Truth about Turmeric for treating Fibromyalgia and Chronic Fatigue Syndrome (CFS). Turmeric for Fibromyalgia & CFS If you've got pain, fatigue, and sleep disorder with fibromyalgia, you may wonder if nature-based dietary supplements can provide you some substitute to relieve yourself. Medical professionals are grappling with the exact question. Think how long a supplement has been used for fibromyalgia symptoms. Newer supplements that have become prevalent in the past 3 or 4 years don't maintain a long track history or record, so the long-term effects aren't known still. However, you may say short-term effects are ascertained. Fibromyalgia is a long-lasting illness that yields pain and tiredness throughout the body, fatigue, and trouble sleeping. Scientists do not entirely understand what pushes it, but people with the disease have an amplified pain sensitivity.

Acute graft versus host disease is a condition in which the graft versus host reaction occurs in the first 3 months of the transplant procedure.Usually it appears in the first 2-4 weeks following transplant.Acute graft versus host disease is characterized by erythematous[reddish] maculopapular skin lesions

https://www.cytotec-pfizer.com/jual-cytotec-jakarta-bandung-jogjakarta/ Jual Obat Cytotec di Jakarta Bandung.Jogjakarta. call 08574 0559 466. by. 18plusmed

The Course is Designed for Healthcare Workers Who Are Looking Into the " Point of Care Ultrasound" to Improve the Management of Acute and Chronic Lung Disease. The lecture on Lung Ultrasound in Critical Care Medicine and Emergency is a lecture by Dr. Federico Conforto. 

Monkeypox: A Clinician Guide is organized by eMedEd. Understand the history of monkeypox, its common modes of transmission, treatment options & available vaccines

A new study published in The Lancet has revealed that a total of 1.7 million people could be living with dementia in England and Wales by 2040. The research highlighted increasing numbers of people who will suffer from Alzheimer's. The disease would massively increase the burden on the healthcare system. The research was led by University of College London (UCL). Lead researcher, Dr Yuntao Chen said, "It is shocking to think that the number of people living with dementia by 2040 may be up to 70 per cent higher than if dementia incidence had continued to decline. "Not only will this have a devastating effect on the lives of those involved but it will also put a considerably larger burden on health and social care than current forecasts predict.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised an innovative and first-of-its-kind gene-editing treatment for sickle-cell disease and transfusion-dependent β-thalassemia. Known as Casgevy (exagamglogene autotemcel), the treatment is based on the innovative gene-editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020. Casgevy is the first medicine to be licensed that uses CRISPR, and it is to be used for treating patients aged 12 and over. To date, a bone marrow transplant has been the only permanent treatment option for these life-long conditions, which in some cases can be fatal. The MHRA's authorisation came after a rigorous assessment of its safety, quality and effectiveness.

Hi friends,good afternoon ,today i will attempt to post an important information regarding vitamin B12[cobalamin] and it's deficiency in strictly vegetarian diets.

Natural food coloring is in demand owing to their health benefits as well. The increased efforts in R&D are helping the major Companies to explore new areas of innovations for food colorant and its applications, providing additional growth opportunities. To know how the food coloring market is going to perform across the world. Read the report summary and Download sample report now @ http://bit.ly/36kZpje

Vitamin B12 helps keep the body's nerve and blood cells healthy. Also, it helps prevent a type of anemia that makes people tired and weak. You can find out more about it on the Canadian pharmacy site https://www.canadapharmacy.com/. I take it daily. But I recommend addressing a doctor first.

In partnership with the pharmaceutical company Boehringer Ingelheim, Leeds Teaching Hospitals Trust (LTHT) has recently established an innovative cardiometabolic clinic. The clinic focuses on reducing cardiovascular risk in people with diabetes who have recently been discharged from LTHT following a heart attack. It is delivered jointly by the cardiology department at Leeds General Infirmary and the diabetes services at the Trust. This is a patient-centred approach to reducing that risk, with pharmacist-delivered clinics scheduled for six to eight weeks after the heart attack. Stephen Wheatcroft, Professor of Cardiometabolic Medicine and Consultant Cardiologist at LTHT, said: "This is an exciting and innovative development, one of the first in the country. Previously, Type 2 diabetic patients presenting with heart issues would have been treated by two separate specialty teams. This is the first time there has been a specific clinic combining the cardiac and diabetes team working together. "We aim to reduce the risk for patients, with earlier multidisciplinary hospital care, to help discharged patients achieve better diabetes control, through improved medication support and optimisation, reducing the need for further treatment and future hospital stays. Overall, it will mean a better patient experience, with improved monitoring and information about treatment options, along with a reduction in waiting times for review in a specialist clinic."

The new deal struck by the NHS will enable provision of a life-saving treatment for babies and young children who suffer with a rare and fatal genetic disease, metachromatic leukodystrophy (MLD). The revolutionary gene therapy treatment, known by its brand name Libmeldy, is used to treat MLD, which causes severe damage to the child's nervous system and organs, leading to a life expectancy of just five to eight years. Having a reported list price of more than £2.8 million, it is the most expensive drug in the world, but can now be offered to young patients on the NHS in England after the health service negotiated a significant confidential discount. the drug works by removing the patient's stem cells and replacing the faulty gene that causes MLD before then re-injecting the treated cells into the patient. The most common form of MLD usually develops in babies younger than 30 months and can cause loss of sight, speech and hearing, as well as difficulty moving, brain impairment, seizures, and eventually death.

IRRITABLE BOWEL SYNDROME,a very common condition affecting many and above all a very discomforting condition.It affects both men & women,but more commonly the females.Irritable bowel syndrome affects the large intestine or the colon.

https://misoprostolhotline.com/jual-cytotec/ Jual misoprostol cytotec makassar Jual Obat Cytotec di Bandung. call 08574 0559 466. by. misoprostolhotline

There is a medicine for it https://herbhomecure.com/dulcoflex-tablet-uses-in-hindi/

Yesterday during my outdoor posting i attended an elderly individual presenting with advanced features of stomach cancer .He was in a lot of anguish and pain.

https://www.mymedistore.com/product/cimivir-400-mg/ Buy Cimivir 400 mg Online - Order Cheapest Cimivir 400 mg from Mymedistore- your most reliable online pharmacy. Avail best price in USA, by your doorsteps.

https://www.cytotec-pfizer.com/tag/jual-cytotec-jakarta/ Jual Obat Cytotec di Jakarta Bandung.Jogjakarta. call 08574 0559 466. by. 18plusmed

Japanese drugmaker Eisai said on Tuesday (January 10) it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease. Nearly all previous experimental drugs using the same approach have failed. The company's application to the European Medicines Agency is based on results from a late-stage study in which the drug was shown to slow down the rate of cognitive decline in patients with early Alzheimer's by 27 per cent, compared with a placebo. Eisai also reiterated its plans to apply for marketing authorization of the drug in Japan by the end of its business year on March 31.

Esperion Therapeutics' non-statin therapy "bempedoic acid" has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial, revealed GlobalData, a leading data and analytics company. As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in near-term based on these results, said GlobalData. According to GlobalData's Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in Australia is expected to increase at a compound annual growth rate of approximately 1.2% from 5.2 million in 2022 to 5.4 million in 2025. Neha Myneni, Pharma Analyst at GlobalData, comments: "Bempedoic acid joins several statin alternatives that have shown the potential to reduce cardiac illnesses. However, with not much significant improvement in the outcomes, there exists a clear room for improvement for non-statin therapies in this space." Bempedoic acid is the sixth class of cholesterol-lowering drugs (other than cholesteryl-ester transfer protein isoform (CETPi) inhibitors), that has demonstrated the potential to reduce heart attacks and strokes. Other class of therapies with similar potential currently marketed in Australia include statins, bile acid resins, niacin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab, and inclisiran).

Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion (£22.67bn), fortifying its rare diseases portfolio in the biggest buyout in the sector this year. The company will pay $116.50 in cash, a premium of nearly 20 per cent to the stock's last close, for each Horizon share. Horizon shares closed up 15 per cent on Monday at $112.36. They had climbed 23.5 per cent through Friday since the company disclosed in late November it was in preliminary talks with Amgen, Sanofi and Johnson & Johnson for potential offers. Amgen shares dipped less than 1 per cent to close at $276.78. Sanofi said Sunday it ended discussions with Horizon after concluding the transaction prices "do not meet our value criteria." J&J also said in early December that it had dropped its pursuit of the deal.

The Health and Social Care Secretary has announced over £175 million funding to boost genomics research in the UK. Through this funding, the government aims to create the most advanced genomic healthcare system in the world. "Patients with cancer and children born with treatable rare genetic diseases are set to benefit from earlier diagnosis and faster access to treatment, following a £175 million boost to cutting-edge genomics research announced by the Health and Social Care Secretary today (Tuesday)," said DHSC. The funding will enable research which could deliver world-leading genomic healthcare to patients, which involves the study of people's DNA. "£105 million to be funded to kickstart a world-leading research study, led by Genomics England in partnership with the NHS, to explore the effectiveness of using whole genome sequencing to find and treat rare genetic diseases in newborn babies," said DHSC. "An initial £26 million to support an innovative cancer programme, led by Genomics England in partnership with the NHS, to evaluate cutting-edge genomic sequencing technology to improve the accuracy and speed of diagnosis for cancer patients and use artificial intelligence to analyse a person's DNA, alongside other information such as routine scans.